There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
NCT05079919
Recruiting
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Severe Hypertriglyceridemia
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: University of Texas Southwestern Medical Center - 1604, Dallas, Texas
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505
Recruiting
PUMA-ALI-4201 is a Phase 2 study evaluating alisertib in patients with pathologically-confirmed extensive-stage small cell lung cancer (ES-SCLC) following progression on or after first-line treatment with platinum-based chemotherapy along with an anti-PDL-1 immunotherapy agent. This study is intended to evaluate the efficacy, safety, and pharmacokinetics of alisertib and to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Small Cell Lung Cancer
Register for Updates
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
NCT05662319
Recruiting
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 wee... Read More
Gender:
Male
Ages:
12 years and above
Trial Updated:
05/09/2024
Locations: Children's Medical Center of Dallas Site Number : 8400018, Dallas, Texas
Conditions: Hemophilia
Register for Updates
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
NCT05203510
Recruiting
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/08/2024
Locations: Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
NCT05277571
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: Up0110 120, Dallas, Texas
Conditions: Atopic Dermatitis
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286
Recruiting
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Register for Updates
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037
Recruiting
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Baylor University Medical Center - Dallas Site Number : 8400011, Dallas, Texas
Conditions: Lung Transplant Rejection
Register for Updates
AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05094336
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or loca... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced MTAP-null Solid Tumors
Register for Updates
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075
Recruiting
Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/08/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Conventional Chondrosarcoma
Register for Updates
A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection
NCT05869643
Recruiting
The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in treatment naïve adult participants living with Human Immunodeficiency Virus Type 1 (HIV-1) infection.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: North Texas Infectious Diseases Consultants, P.A., Dallas, Texas
Conditions: HIV-1-infection
Register for Updates